A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease

Author:

Pritchard Manon F.1,Powell Lydia C.1,Menzies Georgina E.,Lewis Paul D.,Hawkins Karl,Wright Chris,Doull Iolo2,Walsh Timothy R.3,Onsøyen Edvar4,Dessen Arne4,Myrvold Rolf4,Rye Philip D.4,Myrset Astrid H.4,Stevens Howard N. E.5,Hodges Lee A.5,MacGregor Gordon6,Neilly James B.7,Hill Katja E.1,Thomas David W.1

Affiliation:

1. Advanced Therapies Group, School of Dentistry, Cardiff University, Cardiff CF14 4XY, U.K.

2. Respiratory/Cystic Fibrosis Unit, Children’s Hospital for Wales, Cardiff CF14 4XW, U.K.

3. Medical Microbiology, School of Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, U.K.

4. AlgiPharma AS, Sandvika 1337, Norway

5. Bio-Images Drug Delivery Ltd., Glasgow G4 0SF, U.K.

6. Gartnavel Hospital, Glasgow G12 0YN, U.K.

7. Glasgow Royal Infirmary, Glasgow G4 0ET, U.K.

Funder

European Commission

Norges Forskningsr?d

Cystic Fibrosis Foundation

European Social Fund

AlgiPharma AS

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Cited by 70 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3